Apollo Hospitals’ digital and omnichannel venture, Apollo HealthCo, is approaching a pivotal phase where scale, profitability, and capital market readiness are converging.

Senior management indicated that HealthCo is on track to approach a combined revenue run-rate of nearly Rs 20,000 crore this year and is expected to move closer to Rs 25,000 crore by the end of FY27, with a targeted EBITDA margin of 7 percent. This commentary follows a Q3 performance that executives described as driven purely by operating momentum rather than seasonal or one-off tailwinds.

HealthCo houses Apollo’s 7,113 pharmacy outlets, the Apollo 24/7 digital and telehealth platform with more than 46 million registered users, and its expanding presence in diagnostics and insurance distribution. The structure represents a full consumer healthcare stack that spans offline retail, online pharmacy, consultations, diagnostics, and last-mile services.

A critical turning point has been visible in the digital business economics. Platform gross merchandise value rose 28 percent year-on-year to Rs 525 crore in Q3 FY26, while revenue increased 20 percent. More importantly, digital cash losses narrowed sharply to Rs 29.2 crore from about Rs 74 crore in the corresponding quarter last year. This reduction is not being attributed to curtailed growth, but to improvements in customer acquisition efficiency and rising repeat usage from the omnichannel funnel.

HealthCo’s profit after tax nearly tripled year-on-year to Rs 87 crore. Management attributed this to rising transaction volumes, a growing private-label mix of 15.5 percent, and significantly lower marketing spends for user acquisition. The commentary suggests that Apollo’s large offline pharmacy base is now functioning as a low-cost acquisition engine for the digital platform, reducing dependence on paid marketing.

This integration is emerging as the core differentiator. Offline pharmacy distribution continues to generate stable volumes and cash flows, while the digital platform acts as a demand aggregator and retention engine. The company has also expanded diagnostics into 18 new cities through HealthCo channels and continues to scale its insurance distribution segment, indicating that HealthCo is not limited to pharmacy but is evolving into a broader consumer health marketplace.

The confidence around HealthCo’s trajectory is reinforced by the investment made by Advent International in April 2024, when the private equity firm invested Rs 2,475 crore for a 12.1 percent stake. The capital infusion and external validation have laid the groundwork for a potential IPO by the end of FY27 following the composite scheme restructuring.

Alongside HealthCo’s momentum, Apollo’s core hospital business also delivered a steady quarter. Average revenue per inpatient rose 11 percent, driven by higher complexity procedures across oncology, cardiac, neuro, and transplant care. Transplant volumes at the group level increased nearly 50 percent. Hospitals reported a margin of 24.8 percent in Q3, moving closer to the company’s long-stated 25 percent EBITDA aspiration.

Operational efficiencies aided this performance. Management highlighted that shorter lengths of stay, enabled by digital improvements in hospital operations, allowed Apollo to grow patient volumes despite a marginal dip in occupancy. International patient volumes, an important margin lever, rose 28 percent after last year’s base effect linked to Bangladesh subsided.

Executives indicated that Q3’s performance was not episodic and that no material deviation is expected in Q4 in the absence of macro or operational disruptions. Surgical volumes, catheter-based interventions, and international inflows continue to show strength.

Apollo HealthCo’s transition from a cash-burning digital experiment to an approaching scale-profit platform has wider implications for India’s healthcare and consumer internet space. It demonstrates that omnichannel healthcare models, when anchored by physical distribution and clinical infrastructure, can potentially achieve sustainable unit economics.

For Apollo Hospitals, HealthCo is gradually emerging as a second growth engine that could, over time, rival the hospital business in scale and valuation multiples, particularly if the IPO materialises at improved margins.

The development is relevant for investors tracking the convergence of healthcare, retail, and digital platforms. It signals that consumer healthcare platforms in India may be entering a phase where profitability, not just growth, becomes visible. This could influence valuations across listed pharmacy retail, diagnostics chains, and healthtech platforms.

Within healthcare, this reinforces the importance of integrated models that combine offline presence with digital reach. Pharmacy retail, diagnostics distribution, and telehealth are increasingly interconnected rather than standalone verticals.